Tauriga Sciences Inc's Business Segments
Tauriga Sciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Revenue Share by Reportable Segment - Q3 FY2022
- Taurigum0%
- Adjustments Eliminations and Unallocated Items0%
- Pharma0%
Revenue by Reportable Segment - Q3 FY2022
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Taurigum | $ 0 | - |
| Adjustments Eliminations and Unallocated Items | - | 0% |
| Pharma | - | 0% |
Revenue by Product & Service Category - Q3 FY2022
- E Commerce95.5%
- Wholesale3.9%
- Distributor0%
Revenue by Product & Service Category - Q3 FY2022
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| E Commerce | $ 0 | 95.5% |
| Wholesale | $ 0 | 3.9% |
| Distributor | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Tauriga Sciences Inc
The Company entered into an exclusive memorandum of understanding with Immunovative Clinical Research, Inc. (“ICRI”), a Nevada corporation and wholly-owned subsidiary of Immunovative Therapies, Ltd. (“ITL”), an Israeli corporation pursuant to which the Company and ICRI intended to pursue a merger resulting in Novo owning ICRI.